Autologous bone marrow transplantation in acute myeloid leukemia in first remission: first Dutch prospective study.
We have prospectively compared the values of autologous BMT (auto-BMT) and allogeneic marrow transplantation (allo-BMT) in patients (age 15-60 years) with acute myeloid leukemia (AML) who attained complete remission (CR) following remission-induction therapy. In 90/117 cases CR was reached. In 32 of those complete responders auto-BMT was undertaken and in 21 eligible cases HLA-matched allo-BMT. AML relapse was the predominant cause of failure after auto-BMT (17/32). The incidence of relapse after allo-BMT was 6/21. Patients treated with auto-BMT and allo-BMT have an overall survival of 37% and 66% at 3 years posttransplant (P = 0.05). Survival of the nongrafted complete responders is less than 10%. Allo-BMT in adult patients with AML in first complete remission provides a superior outcome when directly compared with the results of auto-BMT.
Löwenberg
B
B
Dr Daniel den Hoed Cancer Center, The Netherlands.
van Putten
W L
WL
Verdonck
L F
LF
Dekker
A W
AW
de Gast
G C
GC
Willemze
R
R
Zwaan
F E
FE
Abels
J
J
Sonneveld
P
P
van der Lelie
J
J
D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D016026:Bone Marrow Transplantation / Q000401:mortality; D003131:Combined Modality Therapy; D003561:Cytarabine / Q000008:administration & dosage; D003630:Daunorubicin / Q000008:administration & dosage; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy / Q000401:mortality / Q000601:surgery*; D008875:Middle Aged; D015337:Multicenter Studies as Topic; D009426:Netherlands / Q000453:epidemiology; D011446:Prospective Studies; D015996:Survival Rate; D013866:Thioguanine / Q000008:administration & dosage; D014182:Transplantation, Autologous; D014184:Transplantation, Homologous
D003561:Cytarabine; D013866:Thioguanine; D003630:Daunorubicin